Capobianco Ivan, Oldhafer Karl J, Fard-Aghaie Mohammed-Hossein, Robles-Campos Ricardo, Brusadin Roberto, Petrowsky Henrik, Linecker Michael, Mehrabi Arianeb, Hoffmann Katrin, Li Jun, Heumann Asmus, Hernandez-Alejandro Roberto, Tun-Abraham Mauro Enrique, Jovine Elio, Serenari Matteo, Bjornsson Bergthor, Sandström Per, Alikhanov Ruslan, Efanov Mikhail, Muiesan Paolo, Schlegel Andrea, van Gulik Thomas M, Olthof Pim B, Stavrou Gregor Alexander, Serna-Higuita Lina Maria, Königsrainer Alfred, Nadalin Silvio
Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Department of General and Abdominal Surgery, Asklepios Hospital Barmbek, Hamburg, Germany.
Hepatobiliary Surg Nutr. 2022 Feb;11(1):52-66. doi: 10.21037/hbsn-21-396.
Preoperative patient selection in Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) is not always reliable with currently available scores, particularly in patients with primary liver tumor. This study aims to (I) to determine whether comorbidities and patients characteristics are a risk factor in ALPPS and (II) to create a score predicting 90-day mortality preoperatively.
Thirteen high-volume centers participated in this retrospective multicentric study. A risk analysis based on patient characteristics, underlying disease and procedure type was performed to identify risk factors and model the Comprehensive ALPPS Preoperative Risk Assessment (CAPRA) score. A nonparametric receiver operating characteristic analysis was performed to estimate the predictive ability of our score against the Charlson Comorbidity Index (CCI), the age-adjusted CCI (aCCI), the ALPPS risk score before Stage 1 (ALPPS-RS1) and Stage 2 (ALPPS-RS2). The model was internally validated applying bootstrapping.
A total of 451 patients were included. Mortality was 14.4%. The CAPRA score is calculated based on the following formula: (0.1 × age) - (2 × BSA) + 1 (in the presence of primary liver tumor) + 1 (in the presence of severe cardiovascular disease) + 2 (in the presence of moderate or severe diabetes) + 2 (in the presence of renal disease) + 2 (if classic ALPPS is planned). The predictive ability was 0.837 for the CAPRA score, 0.443 for CCI, 0.519 for aCCI, 0.693 for ALPPS-RS1 and 0.807 for ALPPS-RS2. After 1,000 cycles of bootstrapping the C statistic was 0.793. The accuracy plot revealed a cut-off for optimal prediction of postoperative mortality of 4.70.
Comorbidities play an important role in ALPPS and should be carefully considered when planning the procedure. By assessing the patient's preoperative condition in relation to ALPPS, the CAPRA score has a very good ability to predict postoperative mortality.
在联合肝脏分隔和门静脉结扎分期肝切除术(ALPPS)中,目前可用的评分系统对术前患者的选择并不总是可靠的,尤其是对于原发性肝癌患者。本研究旨在:(I)确定合并症和患者特征是否为ALPPS的危险因素;(II)创建一个术前预测90天死亡率的评分系统。
13个高容量中心参与了这项回顾性多中心研究。基于患者特征、基础疾病和手术类型进行风险分析,以识别危险因素并建立综合ALPPS术前风险评估(CAPRA)评分模型。进行非参数接受者操作特征分析,以评估我们的评分相对于Charlson合并症指数(CCI)、年龄调整后的CCI(aCCI)、1期前ALPPS风险评分(ALPPS-RS1)和2期ALPPS风险评分(ALPPS-RS2)的预测能力。应用自举法对模型进行内部验证。
共纳入451例患者。死亡率为14.4%。CAPRA评分根据以下公式计算:(0.1×年龄)-(2×体表面积)+1(存在原发性肝癌)+1(存在严重心血管疾病)+2(存在中度或重度糖尿病)+2(存在肾脏疾病)+2(如果计划采用经典ALPPS)。CAPRA评分的预测能力为0.837,CCI为0.443,aCCI为0.519,ALPPS-RS1为0.693,ALPPS-RS2为0.807。经过1000次自举循环后,C统计量为0.793。准确性图显示,术后死亡率最佳预测的截断值为4.70。
合并症在ALPPS中起重要作用,在计划手术时应仔细考虑。通过评估患者与ALPPS相关的术前状况,CAPRA评分具有很好的预测术后死亡率的能力。